Business Description
Atossa Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US04962H5063
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.2 | |||||
3-Year EPS without NRI Growth Rate | 49.5 | |||||
3-Year FCF Growth Rate | 45.5 | |||||
3-Year Book Growth Rate | 8.3 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 37.88 | |||||
9-Day RSI | 44.78 | |||||
14-Day RSI | 48.52 | |||||
6-1 Month Momentum % | -21.22 | |||||
12-1 Month Momentum % | 80.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.35 | |||||
Quick Ratio | 14.35 | |||||
Cash Ratio | 13.96 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -28.16 | |||||
ROA % | -26.81 | |||||
ROIC % | -480.03 | |||||
3-Year ROIIC % | 248.48 | |||||
ROC (Joel Greenblatt) % | -1564.59 | |||||
ROCE % | -33.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.37 | |||||
Price-to-Tangible-Book | 2.35 | |||||
EV-to-EBIT | -3.61 | |||||
EV-to-Forward-EBIT | -2.83 | |||||
EV-to-EBITDA | -3.61 | |||||
EV-to-FCF | -5.9 | |||||
Price-to-Net-Current-Asset-Value | 2.54 | |||||
Price-to-Net-Cash | 2.54 | |||||
Earnings Yield (Greenblatt) % | -27.7 | |||||
FCF Yield % | -9.84 |